V3P: Region Fact Sheet

Size: px
Start display at page:

Download "V3P: Region Fact Sheet"

Transcription

1 V3P: Region Fact Sheet Highlights The 1 region market is 15% of the global market in volume and 63% in value. The regional vaccine procurement habits are different from the rest of the world in several ways, which may serve to inform sustainable supply strategies: one vaccine type exclusive to the region; considerably higher use of single- vs. multi-dose presentations than in the rest of the world; slightly lower use of pre-filled syringes than in the rest of the world; a higher proportion of countries are pool-procuring; HPV, Influenza (adult), Varicella, and Meningococcal vaccines have a higher relative value than in the non- market; three vaccines analysed for price suggest that:»» WAPs in non-gavi, non-paho MICs may be slightly higher in than in the rest of the world. Vaccine Market For the data in the V3P database, the size of the vaccine market in is approximately 15% of the global market by volume, and about 63% by value. However, a majority of HICs from Western Europe do not report price data to the V3P, so the relative size of the global market is higher than reported. The global top 10 vaccines by value are PCV, HPV, Rota, Influenza (seasonal - adult), Varicella, DTP-HepB-Hib, MenA,C,Y,W-135 conj, MenC, DTaP-HepB-Hib- IPV, and BCG, and these 10 account for about 71% of the value of the market in. The relative value of each vaccine type, in each market, is shown in Chart 1 (see page 2). Chart 1 also shows that the primary differences between the and the non- markets are the greater relative values of HPV, Influenza (adult), Varicella, and Meningococcal vaccines in the market. The value of each vaccine is more evenly distributed in the market. The pertussis combination vaccines, PCV, and BCG account for 52% of the non- market compared to only 21% of the market. This regional fact sheet is intended for use by MoH and vaccine procurement staff. The regional fact sheet provides information on all vaccines procured by including analyses of: the presentations used in compared to the rest of the world; the procurement methods used in compared to the rest of the world; value to the market of the most frequently reported vaccines to the V3P from and the rest of the world; prices paid by, compared to rest of the world. Increased knowledge about several aspects of vaccine market and purchasing may help to inform the development of policies related to market shaping and vaccine access. The Vaccine Product Price & Procurement (V3P) initiative was launched to provide all countries with a platform for greater vaccine price & procurement transparency. The initiative collects data through the WHO and UNICEF Joint Reporting Form, and analyses and distributes information to relevant stakeholders to inform policy making and procurement processes. As of July 2017, the database contained data from 142 countries. The fact sheet is exclusively based on the data reported through the JRF & V3P initiative, as of July Pool-procurement refers to vaccines procured through UNICEF SD and the PAHO Revolving Fund. Readers may access additional vaccine price and procurement information from reporting countries and procurement agencies (UNICEF and PAHO) on the V3P website ( v3p) or by contacting v3p-project@ who.int. 1 countries contributing to the V3P: Argentina, Brazil, Chile, Costa Rica, Cuba, Dominican Republic, Ecuador, Grenada, Guyana, Jamaica, Mexico, Nicaragua, Paraguay, Peru, Saint Lucia, Suriname, Trinidad and Tobago, United States of America, Uruguay. countries not contributing to the V3P: Antigua and Barbuda, Bahamas, Barbados, Belize, Bolivia, Canada, Colombia, Dominica, El Salvador, Guatemala, Haiti, Honduras, Panama, Saint Kitts and Nevis, Saint Vincent and the Grenadines, Venezuela. WORKING DOCUMENT November

2 Chart 1. The relative value of the global top 10 vaccines in the and non- markets. non- Products and Presentations uses 35 vaccine types out of 57 reported by non- countries. One vaccine type (DTaP-HepB-IPV) is exclusive to. uses five out of seven of the presentations used in non- countries (Uniject and an intranasal sprayer are reported from non- but at a frequency of <1% - not shown). There is, however, a slightly lower prevalence of prefilled syringes and ampoules in than in non- countries (16% versus 17%, and 3% versus 8%, respectively). Chart 2 shows a considerably greater predominance of single-dose presentations in compared to non- countries (63% versus 47%), and a lower prevalence of 20- dose presentations (7%) than in non- countries (17%). Chart 2. Prevalence of presentation sizes in and non- countries. non- WORKING DOCUMENT November

3 Procurement Method has a higher predominance of pool-procurement (68%), compared to non- regions (52%) (see Chart 3). Self-procurement in is about half as prevalent as in non- countries (16% versus 34%). The higher proportion of poolprocurement in is a consequence of the PAHO Revolving Fund which a majority of countries use for vaccine procurement. Vaccine Prices There is very limited data for non-gavi, non- PAHO MICs in, but for three vaccines analysed, WAPs in were 2 to 19% higher than for the same single-dose vaccines in the non- market (see Chart 4). Chart 3. Prevalence of procurement method in and non- countries. non- Chart 4. WAPs for three select single-dose vaccines in self-procuring non-gavi, non- PAHO MICs in and non-, in Minimum, maximum, and median prices for vaccines procured in are shown in Table 1 (see page 4). Vaccine Availability Reported manufacturers from and globally, for each vaccine type, are shown in Table 2 (see page 5). 2 Vaccines were selected on the basis of sufficient data for analyses data for single-dose presentations from at least two countries in both and non-. WORKING DOCUMENT November

4 Table 1. Proportion of countries self-procuring, minimum, median, and maximum prices, number of products, and number of manufacturers for each vaccine type reported from at least five countries, in Vaccine type (ranked by frequency of use) % of countries self-procuring in price (all procurement methods, all income groups): lowest (presentation size) / highest (presentation size) / median N different products in N manufacturers in N manufacturers reported globally MMR 22 $0.60 (10-dose) / $40.00 (1-dose) / $ IPV 6 $1.73 (5-dose) / $12.72 (1-dose) / $ Influenza (seasonal adult) 29 $1.97 (10-dose) / $25.07 (1-dose) / $ BCG 20 $0.14 (20-dose) / $0.94 (10-dose) / $ bopv1,3 7 $0.12 (20-dose) / $0.25 (20-dose) / $ YF 7 $1.05 (10-dose) / $35.46 (1-dose) / $ DTP-HepB-Hib 8 $2.00 (1-dose) / $4.00 (1-dose) / $ Td 31 $0.10 (10-dose) / $19.69 (1-dose) / $ HepB (adult) 23 $0.19 (10-dose) / $28.55 (1-dose) / $ DTP 15 $0.20 (10-dose) / $1.20 (10-dose) / $ PCV 17 $3.30 (1-dose) / $ (1-dose) / $ HPV 42 $3.74 (1-dose) / $ (1-dose) / $ Varicella 27 $14.10 (1-dose) / $88.34 (1-dose) / $ Rota 20 $2.50 (1-dose) / $86.75 (1-dose) / $ DT 0 $0.08 (10-dose) / $0.98 (10-dose) / $ Rabies 20 $6.30 (1-dose) / $16.13 (1-dose) / $ Pneumo ps 33 $6.14 (1-dose) / $46.40 (1-dose) / $ HepB (ped) 25 $0.20 (1-dose) / $12.30 (1-dose) / $ Influenza (seasonal ped) 25 $1.35 (20-dose) / $19.14 (1-dose) / $ Hib 14 $1.95 (1-dose) / $12.48 (1-dose) / $ DTaP 29 $10.85 (1-dose) / $16.85 (1-dose) / $ HepA (ped) 50 $6.70 (1-dose) / $18.23 (1-dose) / $ MR 20 $0.63 (10-dose) / $2.25 (1-dose) / $ MenA,C,Y,W-135 conj 40 $20.30 (1-dose) / $89.16 (1-dose) / $ WORKING DOCUMENT November

5 Table 2. Vaccine manufacturers reported by countries, and additional manufacturers reported from other regions but not from. Vaccine type Manufacturers reported by countries Additional manufacturers not reported by BCG FAP (Fundação Ataulpho de Paiva); InterVax; Japan BCG Laboratory; Serum Institute of India AJ Vaccines A/S; BB-NCIPD; Biomed Lublin; China CNBG; GreenSignal Bio Pharma Limited; Institut Pasteur Iran; Institut Pasteur Tunis; IVAC (Institute of Vaccines and Medical Biologicals); Mikrogen; PT Bio Farma (Persero); Thai Red Cross Society; Torlak Institute of Virology, Vaccines and Sera bopv1,3 Bharat Biotech; Birmex; Serum Institute of India Boryung Biopharma; China CNBG; GSK; Haffkine Bio; PT Bio Farma (Persero); Razi Institute Iran; Sanofi Pasteur DT BB-NCIPD; Biological E; InterVax; Serum Institute of India Arabio; China CNBG; Mikrogen; PT Bio Farma (Persero); Razi Institute Iran; Sanofi Pasteur; Torlak Institute of Virology, Vaccines and Sera DTaP GSK; Sanofi Pasteur China CNBG DTP DTP-HepB-Hib Biological E; Boryung Biopharma; Butantan; PT Bio Farma (Persero); Serum Institute of India Biological E; Centro de Ingeniería Genética y Biotecnología; Panacea Biotec; Serum Institute of India IVAC (Institute of Vaccines and Medical Biologicals); Mikrogen; Torlak Institute of Virology, Vaccines and Sera Arabio; Bharat Biotech; GSK; Janssen; LG Life Sciences; PT Bio Farma (Persero); Shantha Biotechnics Private Limited HepA (ped) Butantan; GSK; Merck Vaccines; Sanofi Pasteur Changchun Changsheng Life Sciences Ltd.; China CNBG; Institute of Medical Biology Chinese Academy of Medical Sciences; Sinovac; Zhejiang Pukang HepB (adult) Centro de Ingeniería Genética y Biotecnología; GSK; LG Life Sciences; Merck Vaccines; Serum Institute of India Berna Biotech Korea; Institut Pasteur Iran; Janssen; Mikrogen; Shantha Biotechnics Private Limited HepB (ped) GSK; Merck Vaccines; Serum Institute of India Biokangtai; China CNBG; Dalian Hissen; Janssen; LG Life Sciences; Mikrogen; NCPC GeneTech; PT Bio Farma (Persero); Sanofi Pasteur MSD; VABIOTECH Hib Merck Vaccines; Sanofi Pasteur; Serum Institute of India GSK HPV Butantan; GSK; Merck Vaccines; Sinergium None Influenza (adult) Abbott Biologicals B.V.; Butantan; Green Cross Corporation; Sanofi Pasteur; Seqirus; Sinergium Influenza (ped) Green Cross Corporation; Sanofi Pasteur; Seqirus; Sinergium Mikrogen; Npo Petrovaks GPO-MBP Co., Ltd.; GSK; Hualan Biological Bacterin Co., Ltd; Mikrogen; Npo Petrovaks IPV Bilthoven Biologicals; Sanofi Pasteur GSK; Institute of Medical Biology Chinese Academy of Medical Sciences; PT Bio Farma (Persero); Serum Institute of India; Shantha Biotechnics Private Limited MenACYW-135 conj GSK; Pfizer; Sanofi Pasteur Arabio MMR Merck Vaccines; Sanofi Pasteur; Serum Institute of India China CNBG; GSK MR Serum Institute of India Beijing Minhai Biotech; China CNBG PCV GSK; Pfizer None Pneumo ps Merck Vaccines; Sanofi Pasteur None Rabies Bharat Biotech; Butantan; Sanofi Pasteur Chiron Behring Vaccines Private Ltd.; FSUE Chumakov; GSK; Novartis Rotavirus GSK; Merck Vaccines Bharat Biotech Td BB-NCIPD; Biological E; Butantan; InterVax; Sanofi Pasteur; Serum Institute of India Varicella Green Cross Corporation; Merck Vaccines; Sinergium GSK AJ Vaccines A/S; Boryung Biopharma; GSK; Mikrogen; PT Bio Farma (Persero); Razi Institute Iran; Torlak Institute of Virology, Vaccines and Sera YF Bio-Manguinhos; Sanofi Pasteur FSUE Chumakov; Institut Pasteur Dakar DISCLAIMER Information contained in the V3P database is provided by participating countries and/or organizations procuring on behalf of countries that have agreed to share vaccine price and procurement data with V3P. Participating countries are solely responsible for the accuracy of the data provided. The information contained in the V3P database does not in any way imply an endorsement, certification, warranty of fitness or recommendation by WHO of any company or product for any purpose, and does not imply preference over products of a similar nature that are not mentioned. WHO furthermore does not warrant that: (1) the information is complete and/or error free; and/or that (2) the products listed are of acceptable quality, have obtained regulatory approval in any country, or that their use is otherwise in accordance with the national laws and regulations of any country, including but not limited to patent laws. Inclusion of products in the database does not furthermore imply any approval by WHO of the products in question (which is the sole prerogative of national authorities). WHO will not accept any liability or responsibility whatsoever for any injury, death, loss, damage, or other prejudice of any kind that may arise as a result of, or in connection with the procurement, distribution and use of any product listed in the V3P database. WORKING DOCUMENT November

V3P: Region Fact Sheet

V3P: Region Fact Sheet V3P: Region Fact Sheet Highlights The 1 region market is 4% of the global market in volume and 5% in value. The regional vaccine procurement habits are different from the rest of the world in several ways,

More information

V3P: Region Fact Sheet

V3P: Region Fact Sheet V3P: Region Fact Sheet Highlights The 1 region market is 6% of the world market in volume and 6% in value. The regional vaccine procurement habits are different from the rest of the world in several ways,

More information

V3P: Key Findings for HPV

V3P: Key Findings for HPV V3P: Key Findings for HPV HPV Highlights At present, only 41% of all countries, predominantly higher income countries, have introduced HPV; Nevertheless, HPV is the second highest value vaccine reported

More information

Pandemic (H1N1) (August 14, h GMT; 12 h EST) Update on the Qualitative Indicators

Pandemic (H1N1) (August 14, h GMT; 12 h EST) Update on the Qualitative Indicators Regional Update Pandemic (H1N1) 2009 (August 14, 2009-17 h GMT; 12 h EST) Update on the Qualitative Indicators For epidemiological week 31 (EW 31, August 2 to August 8) 17 countries have reported updated

More information

Regional Update Pandemic (H1N1) 2009 (March 15, h GMT; 12 h EST)

Regional Update Pandemic (H1N1) 2009 (March 15, h GMT; 12 h EST) Regional Update Pandemic (H1N1) 2009 (March 15, 2010-17 h GMT; 12 h EST) The information contained within this update is obtained from data provided by Ministries of Health of Member States and National

More information

Regional Update Pandemic (H1N1) 2009

Regional Update Pandemic (H1N1) 2009 Regional Update Pandemic (H1N1) 2009 (September 04, 2009-22 h GMT; 17 h EST) Update on the Qualitative Indicators For Epidemiological Week 34 (EW 34), from 23 August to 29 August, 20 countries reported

More information

Pandemic (H1N1) (August 28, h GMT; 12 h EST) Update on the qualitative indicators

Pandemic (H1N1) (August 28, h GMT; 12 h EST) Update on the qualitative indicators Regional Update Pandemic (H1N1) 29 (August 28, 29-17 h GMT; 12 h EST) Update on the qualitative indicators For Epidemiological Week 33 (EW 33), from 16 August to 22 August, 22 countries reported updated

More information

Regional Update Pandemic (H1N1) 2009

Regional Update Pandemic (H1N1) 2009 Regional Update Pandemic (H1N1) 2009 (September 18, 2009-22 h GMT; 17 h EST) Update on the Qualitative Indicators For Epidemiological Week 36 (EW 36), from 6 September to 12 September, 17 countries reported

More information

ASSESSMENT OF IMPACTS OF AIR POLLUTION ON HEALTH

ASSESSMENT OF IMPACTS OF AIR POLLUTION ON HEALTH ASSESSMENT OF IMPACTS OF AIR POLLUTION ON HEALTH Michal Krzyzanowski WHO ECEH Bonn Office 1 Exposure - Response Population X Exposure IMPACT ESTIMATE FOR POPULATION X Population X health status WHO Air

More information

Regional Update Pandemic (H1N1) 2009 (July 19, h GMT; 12 h EST)

Regional Update Pandemic (H1N1) 2009 (July 19, h GMT; 12 h EST) Regional Update Pandemic (H1N1) 9 (July 19, - 17 h GMT; 12 h EST) The information contained within this update is obtained from data provided by Ministries of Health of Member States and National Influenza

More information

Regional Update Pandemic (H1N1) 2009 (July 6, h GMT; 12 h EST)

Regional Update Pandemic (H1N1) 2009 (July 6, h GMT; 12 h EST) Regional Update Pandemic (H1N1) 29 (July 6, 21-17 h GMT; 12 h EST) The information contained within this update is obtained from data provided by Ministries of Health of Member States and National Influenza

More information

Regional Update Pandemic (H1N1) 2009 (January 19, h GMT; 12 h EST)

Regional Update Pandemic (H1N1) 2009 (January 19, h GMT; 12 h EST) Regional Update Pandemic (H1N1) 2009 (January 19, - 17 h GMT; 12 h EST) The information contained within this update is obtained from data provided by Ministries of Health of Member States and National

More information

50th DIRECTING COUNCIL 62nd SESSION OF THE REGIONAL COMMITTEE

50th DIRECTING COUNCIL 62nd SESSION OF THE REGIONAL COMMITTEE PAN AMERICAN HEALTH ORGANIZATION WORLD HEALTH ORGANIZATION 50th DIRECTING COUNCIL 62nd SESSION OF THE REGIONAL COMMITTEE Washington, D.C., USA, 27 September-1 October 2010 Agenda Item 4.17 27 September

More information

Regional Update Pandemic (H1N1) 2009 (December 1, h GMT; 12 h EST)

Regional Update Pandemic (H1N1) 2009 (December 1, h GMT; 12 h EST) Regional Update Pandemic (H1N1) 2009 (December 1, 2009-17 h GMT; 12 h EST) The information contained within this update is obtained from data provided by Ministries of Health of Member States and National

More information

Regional Update Pandemic (H1N1) 2009 (July 31, h GMT; 17 h EST) Update on the Qualitative Indicators Epidemiological Week 29 intensity

Regional Update Pandemic (H1N1) 2009 (July 31, h GMT; 17 h EST) Update on the Qualitative Indicators Epidemiological Week 29 intensity Regional Update Pandemic (H1N1) 2009 (July 31, 2009-22 h GMT; 17 h EST). Update onn thhe t Quual lli iit tati iivve InndiI iicatorss As of Epidemiological Week 29 (EW 29, July 19 to 25) all the 35 countries

More information

Hepatitis B and C in the Spotlight: A public health response in the Americas. Key Messages

Hepatitis B and C in the Spotlight: A public health response in the Americas. Key Messages 2017 highlights Hepatitis B and C in the Spotlight: A public health response in the Americas Key Messages Regarding the national structures developed to support the response to the viral hepatitis epidemics,

More information

Regional Update Pandemic (H1N1) 2009 (May 24, h GMT; 12 h EST)

Regional Update Pandemic (H1N1) 2009 (May 24, h GMT; 12 h EST) Regional Update Pandemic (H1N1) 2009 (May 24, 2010-17 h GMT; 12 h EST) The information contained within this update is obtained from data provided by Ministries of Health of Member States and National

More information

DR. CLAUDINA E. CAYETANO REGIONAL MENTAL ADVISOR Pan-American Health Organization/ World Health Organization

DR. CLAUDINA E. CAYETANO REGIONAL MENTAL ADVISOR Pan-American Health Organization/ World Health Organization DR. CLAUDINA E. CAYETANO REGIONAL MENTAL ADVISOR Pan-American / World Outline Facts and Figures Suicide a major Public problem Suicide in the Americas Risk and Protective factors and related interventions

More information

WHO s activities, guidance, recommendations to avoid or mitigate vaccine supply shortages

WHO s activities, guidance, recommendations to avoid or mitigate vaccine supply shortages Viral Hepatitis Prevention Board LISBON, PORTUGAL 15-16 March 2018 WHO s activities, guidance, recommendations to avoid or mitigate vaccine supply shortages Dr Oleg Benes Vaccine-preventable Diseases and

More information

Global Vaccine Market Report

Global Vaccine Market Report Global Vaccine Market Report Executive Summary In response to repeated calls from WHO Member States, WHO launched the Market Information for Access to Vaccines (MI4A) initiative to enhance vaccine market

More information

Special Topic. The ten leading causes of death in countries of the Americas

Special Topic. The ten leading causes of death in countries of the Americas The ten leading causes of death in countries of the Americas Table 1: Country specific information on the ten leading causes of death in broad age groups, by sex, for the latest two or three data years

More information

Investigating Disease Epidemics through Simulation with a focus on Chikungunya in the Americas

Investigating Disease Epidemics through Simulation with a focus on Chikungunya in the Americas Investigating Disease Epidemics through Simulation with a focus on Chikungunya in the Americas Alexandra L. Stone and Jean C. Galan-Rivera Mentors: Dr. Jacob Oleson and Dr. Grant Brown ISIB 2015 University

More information

countries do not have information available for this indicator.

countries do not have information available for this indicator. Regional Update Pandemic (H1N1) 2009 (July 22, 2009-22 h GMT; 17 h EST) The data and information in this report will be updated on a weekly basis and available at: http://new.paho.org/hq/index.php?option=com_content&task=blogcategory&id=814&itemid=1206

More information

Regional Update Influenza (August 16, h GMT; 12 h EST)

Regional Update Influenza (August 16, h GMT; 12 h EST) Regional Update Influenza (August 16, 21-17 h GMT; 12 h EST) The information contained within this update is obtained from data provided by Ministries of Health of Member States and National Influenza

More information

FOURTH ANNUAL VACCINATION WEEK IN THE AMERICAS (VWA 2006) FINAL REPORT

FOURTH ANNUAL VACCINATION WEEK IN THE AMERICAS (VWA 2006) FINAL REPORT Immunization Unit Community and Family Health Area FOURTH ANNUAL VACCINATION WEEK IN THE AMERICAS (VWA 2006) FINAL REPORT 22-29 April 2006 Background Vaccination Week in the Americas (VWA) is an initiative

More information

Tobacco Control Report for the Region of the Americas

Tobacco Control Report for the Region of the Americas Tobacco Control Report for the Region of the Americas Adult Current Smoking Prevalence * Antigua and Barbuda The Bahamas Barbados Dominica Grenada Saint Kitts and Nevis Saint Lucia Saint Vincent and the

More information

How and Why Vaccines Are Developed by Industry. Stanley A. Plotkin

How and Why Vaccines Are Developed by Industry. Stanley A. Plotkin How and Why Vaccines Are Developed by Industry Stanley A. Plotkin Merieux 2012 1 Why Vaccines are Different than Drugs 1) Given to healthy people, high safety required 2) Larger governmental role 3) Low

More information

REVELAC-i: Progress in measuring influenza vaccine effectiveness in Latin America and way forward

REVELAC-i: Progress in measuring influenza vaccine effectiveness in Latin America and way forward REVELAC-i: Progress in measuring influenza vaccine effectiveness in Latin America and way forward SARInet annual meeting, Punta Cana, May 23 2017 Nathalie El Omeiri On behalf of REVELAC-i network, Alba

More information

Influenza Vaccine Use In the Americas

Influenza Vaccine Use In the Americas Influenza Vaccine Use In the Americas Network for Evaluation of Influenza Vaccine Effectiveness REVELAC-i Alba Maria Ropero-Alvarez Comprehensive Family Immunization Unit PAHO/FGL/IM Global Vaccine and

More information

OVERVIEW OF THE POLIO ERADICATION AND ENDGAME STRATEGIC PLAN AND THE topv TO bopv SWITCH

OVERVIEW OF THE POLIO ERADICATION AND ENDGAME STRATEGIC PLAN AND THE topv TO bopv SWITCH OVERVIEW OF THE POLIO ERADICATION AND ENDGAME STRATEGIC PLAN AND THE topv TO bopv SWITCH Dr. Karen Lewis-Bell Advisor, Immunization Switch Monitoring Training Jamaica, December 9, 2015 Presentation Outline

More information

Vaccine Pricing: Gavi Transitioning Countries

Vaccine Pricing: Gavi Transitioning Countries Vaccine Pricing: Gavi Transitioning Countries All prices shown in this document are Unicef awarded price per dose (in USD), per product, per supplier, per calendar year, based on multi-year supply agreements.

More information

Global vaccine market

Global vaccine market Global vaccine market Global Vaccine and Immunization Research Forum Amie Batson Chief Strategy Officer, PATH March 2016 PATH/Eric Becker Agenda Overview of global vaccine market Demand Supply Financing

More information

CD29/23 Page 2. (Eng.) EXPANDED PROGRAM ON IMMUNIZATION IN THE AMERICAS. Progress Report by the Director. 1. Background and Policy Basis

CD29/23 Page 2. (Eng.) EXPANDED PROGRAM ON IMMUNIZATION IN THE AMERICAS. Progress Report by the Director. 1. Background and Policy Basis directing council PAN AMERICAN HEALTH ORGANIZATION regional committee WORLD HEALTH ORGANIZATION XXIX Meeting Washington, D.C. September-October 1983 XXXV Meeting INDEXEo L I I Provisional Agenda Item 23

More information

Analysis of Immunization Financing Indicators from the WHO-UNICEF Joint Reporting Form (JRF),

Analysis of Immunization Financing Indicators from the WHO-UNICEF Joint Reporting Form (JRF), Analysis of Immunization Financing Indicators from the WHO-UNICEF Joint Reporting Form (JRF), 2008-2010 Claudio Politi and Oumar Sagna Department of Immunization Vaccines and Biologicals, World Health

More information

ECONOMICS OF THE VACCINE MARKET: SIZE, GROWTH AND REVENUES

ECONOMICS OF THE VACCINE MARKET: SIZE, GROWTH AND REVENUES ECONOMICS OF THE VACCINE MARKET: SIZE, GROWTH AND REVENUES 1 Relationship between research funding and burden of disease Source: Global Forum for Health Research Monitoring Financial Flows for Health Research

More information

Sustaining Immunization in Developing Countries: The Future We Make

Sustaining Immunization in Developing Countries: The Future We Make Sustaining Immunization in Developing Countries: The Future We Make Global Health Summit Denver, CO 29 April 211 Jon Kim Andrus, MD Deputy Director Umbrella of protection in the Americas Measles eradication

More information

Managing constrained vaccine supply: prevention and remediation Lessons learned and ways forward DVCMN Annual Meeting October Bangkok,

Managing constrained vaccine supply: prevention and remediation Lessons learned and ways forward DVCMN Annual Meeting October Bangkok, Managing constrained vaccine supply: prevention and remediation Lessons learned and ways forward DVCMN Annual Meeting October 5-7 2015 Bangkok, Thailand UNICEF has a key role in vaccine procurement and

More information

Human Papillomavirus and Related Cancers

Human Papillomavirus and Related Cancers Human Papillomavirus and Related Cancers Summary Report Update. September 15, 2010. AMERICAS - ii - Rights c WHO/ICO Information Centre on HPV and Cervical Cancer (HPV Information Centre) 2010 All rights

More information

Health for All THE EXPANDED PROGRAM ON IMMUNIZATION IN THE AMERICAS: A REVIEW

Health for All THE EXPANDED PROGRAM ON IMMUNIZATION IN THE AMERICAS: A REVIEW l ABSTRACTS AND REPORTS 307 soon undertaken. This campaign relied principally on the media and community involvement. Media activities included the following: l A commercial firm was invited to prepare

More information

Championing Health: Sustainable Development and Equity. PAHO Strategic Plan

Championing Health: Sustainable Development and Equity. PAHO Strategic Plan Championing Health: Sustainable Development and Equity PAHO Strategic Plan 2014-2019 PAHO Strategic Plan 2014-2019 While we celebrate important achievements, we recognize that much remains to be accomplished.

More information

Protecting people against known and emerging infectious diseases globally

Protecting people against known and emerging infectious diseases globally Protecting people against known and emerging infectious diseases globally 18 October 2017 SAGE Geneva By Mahima Datla President, DCVMN 1 Agenda Introduction to DCVMN DCVMN s contributions Suggested areas

More information

Senior Management Team Meeting Target setting in Latin America

Senior Management Team Meeting Target setting in Latin America Senior Management Team Meeting Target setting in Latin America October 2006 Nancy Andrade-Castro RST Latin America Geneva/2006 For all enquiries, please contact Nancy Andrade-Castro, Acting Director for

More information

Global Vaccine Market Features and Trends

Global Vaccine Market Features and Trends Global Vaccine Market Features and Trends Miloud Kaddar Senior Adviser, Health Economist 1 WHO, IVB, Geneva GLOBAL VACCINE MARKET MAIN FEATURES OF THE VACCINE MARKET? NEW TRENDS SINCE 2000? IMPLICATIONS?

More information

_flu.asp. region States. North. The Caribbean and. South. region. South

_flu.asp. region States. North. The Caribbean and. South. region. South Regional Update EW 48, 2013 Influenza and other respiratory viruses (December 11, 2013) PAHO interactive influenza data: Uhttp://ais.paho.org/phip/viz/ed flu.asp Influenza Regional Reports: www.paho.org/reportesinfluenza

More information

Regional Update EW 09 Influenza (March 15, h GMT; 12 h EST)

Regional Update EW 09 Influenza (March 15, h GMT; 12 h EST) Regional Update EW 09 Influenza (March 15, 2011-17 h GMT; 12 h EST) The information presented in this update is based on data provided by Ministries of Health and National Influenza Centers of Member States

More information

Figure 1: Case Distribution of Dengue Hemorrhagic Fever, in %, by subregion, *This includes cases of dengue with complications.

Figure 1: Case Distribution of Dengue Hemorrhagic Fever, in %, by subregion, *This includes cases of dengue with complications. Regional Update on Dengue (17 March 2009) Situation of Dengue in the Americas, 2008 Dengue is an endemic disease in most of the countries of the Americas and, over the past 20 years, has shown sustained

More information

V3P PRICE DIGEST VACCINE PRODUCT, PRICE AND PROCUREMENT. WORKING DOCUMENT 2016 edition

V3P PRICE DIGEST VACCINE PRODUCT, PRICE AND PROCUREMENT. WORKING DOCUMENT 2016 edition V3P PRICE DIGEST VACCINE PRODUCT, PRICE AND PROCUREMENT WORKING DOCUMENT 2016 edition This document has been prepared by the Expanded Programme on Immunization (EPI) of the Department of Immunization,

More information

Country Length Discount Travel Period Anguilla All 20% off 08/24/11 12/15/11 Antigua All 20% off 08/24/11 12/15/11 Argentina All 20% off 08/24/11

Country Length Discount Travel Period Anguilla All 20% off 08/24/11 12/15/11 Antigua All 20% off 08/24/11 12/15/11 Argentina All 20% off 08/24/11 Country Length Discount Travel Period Anguilla All 20% off 08/24/11 12/15/11 Antigua All 20% off 08/24/11 12/15/11 Argentina All 20% off 08/24/11 12/15/11 Aruba All 20% off 08/24/11 12/15/11 Australia

More information

50th DIRECTING COUNCIL 62nd SESSION OF THE REGIONAL COMMITTEE

50th DIRECTING COUNCIL 62nd SESSION OF THE REGIONAL COMMITTEE PAN AMERICAN HEALTH ORGANIZATION WORLD HEALTH ORGANIZATION 50th DIRECTING COUNCIL 62nd SESSION OF THE REGIONAL COMMITTEE Washington, D.C., USA, 27 September-1 October 2010 Provisional Agenda Item 4.10

More information

Photo: Barbados VWA 2015 VACCINATION WEEK IN THE AMERICAS 2015 FINAL REPORT. Boost your power! Get Vaccinated!

Photo: Barbados VWA 2015 VACCINATION WEEK IN THE AMERICAS 2015 FINAL REPORT. Boost your power! Get Vaccinated! Photo: Barbados VWA 2015 VACCINATION WEEK IN THE AMERICAS 2015 FINAL REPORT 25 APRIL- 2 MAY 2015 Boost your power! Get Vaccinated! 0 Contents VWA Background... 2 VWA Objectives... 2 The Path to World Immunization

More information

TABLE 7 ADVANTAGES AND DISADVANTAGES OF TOXOID VACCINES SUBUNIT VACCINES Applications of Subunit Vaccines TABLE 8 APPLICATIONS OF

TABLE 7 ADVANTAGES AND DISADVANTAGES OF TOXOID VACCINES SUBUNIT VACCINES Applications of Subunit Vaccines TABLE 8 APPLICATIONS OF CHAPTER ONE: INTRODUCTION... 1 STUDY OBJECTIVES... 1 REASONS FOR DOING THIS STUDY... 1 INTENDED AUDIENCE... 2 SCOPE OF THE STUDY... 2 METHODOLOGY... 2 INFORMATION SOURCES... 2 ABOUT THE AUTHOR... 3 RELATED

More information

Regional Update EW 31, 2014 Influenza and other respiratory viruses (August 12, 2014)

Regional Update EW 31, 2014 Influenza and other respiratory viruses (August 12, 2014) Regional Update EW 31, 2014 Influenza and other respiratory viruses (August 12, 2014) PAHO interactive influenza data: Uhttp://ais.paho.org/phip/viz/ed_flu.asp Influenza Regional Reports: www.paho.org/influenzareports

More information

Cervical Cancer Control in Latin America and the Caribbean ROUNDTABLE POLICY BRIEF. Dr Rolando Camacho Rodríguez

Cervical Cancer Control in Latin America and the Caribbean ROUNDTABLE POLICY BRIEF. Dr Rolando Camacho Rodríguez Cervical Cancer Control in Latin America and the Caribbean ROUNDTABLE POLICY BRIEF Dr Rolando Camacho Rodríguez ABBREVIATIONS CIN DIRAC HPV IAEA IARC LAC LEEP LMIC MoH NCCP NCI NGO PAHO RINC TEC VIA VIL

More information

Intellectual Property Rights & Vaccines in Developing Countries

Intellectual Property Rights & Vaccines in Developing Countries Intellectual Property Rights & Vaccines in Developing Countries by Dr. S.S.Jadhav President DCVMN Developing Country Vaccine Manufacturers Network DCVMN Formed in November 2000. 7 members steering committee.

More information

China Human Vaccine Industry Report, Mar. 2015

China Human Vaccine Industry Report, Mar. 2015 China Human Vaccine Industry Report, 2015-2018 Mar. 2015 STUDY GOAL AND OBJECTIVES This report provides the industry executives with strategically significant competitor information, analysis, insight

More information

PAN AMERICAN HEALTH ORGANIZATION WORLD HEALTH ORGANIZATION. directing council 6NDEXED. regional committee. XXXVII Meeting

PAN AMERICAN HEALTH ORGANIZATION WORLD HEALTH ORGANIZATION. directing council 6NDEXED. regional committee. XXXVII Meeting directing council PAN AMERICAN HEALTH ORGANIZATION regional committee WORLD HEALTH ORGANIZATION XXXI Meeting Washington, D.C. September-October 1985 XXXVII Meeting 6NDEXED Provisional Agenda Item 22 CD31/7

More information

Introduction of New Vaccines in Latin America and the Caribbean: Decision-Making LUCIA HELENA DE OLIVEIRA AND BARBARA JAUREGUI

Introduction of New Vaccines in Latin America and the Caribbean: Decision-Making LUCIA HELENA DE OLIVEIRA AND BARBARA JAUREGUI Introduction of New Vaccines in Latin America and the Caribbean: Decision-Making LUCIA HELENA DE OLIVEIRA AND BARBARA JAUREGUI 2 Introduction of New Vaccines in Latin America and the Caribbean: Decision-Making

More information

Main developments in past 24 hours

Main developments in past 24 hours ECDC DAILY UPDATE Pandemic (H1N1) 2009 Update 02 October 2009, 09:00 hours CEST Main developments in past 24 hours Weekly Influenza Surveillance Overview to be published today; Media highlights and Eurosurveillance

More information

Pneumococcal Symposium

Pneumococcal Symposium 3 rd Regional Pneumococcal Symposium 13-14 14 February 2008 Istanbul, Turkey Dr. Akira Homma Bio-Manguinhos, Fiocruz DCVMN Developing Countries Vaccine Manufacturers Network -DCVMN- Formed in 2000, Bandung,

More information

China Human Vaccine Industry Report, Jun. 2016

China Human Vaccine Industry Report, Jun. 2016 China Human Vaccine Industry Report, 2016-2020 Jun. 2016 STUDY GOAL AND OBJECTIVES This report provides the industry executives with strategically significant competitor information, analysis, insight

More information

Taking vaccine effectiveness into public health decision making: The ProVac Example

Taking vaccine effectiveness into public health decision making: The ProVac Example http://www.paho.org/provac Taking vaccine effectiveness into public health decision making: The ProVac Example Evaluating dengue effectiveness workshop June 12 th, 2014 Washington, DC Cara Bess Janusz

More information

Barbados. Tobacco Control Report Current Tobacco Use Prevalence 34.5% 23.2% 13%

Barbados. Tobacco Control Report Current Tobacco Use Prevalence 34.5% 23.2% 13% Barbados Tobacco Control Report 2011 Current Tobacco Use Prevalence 34.5% 13% 23.2% 3% Male Female Adult Male Female Youth NOTES: Adult data: percentage of the population 15 years and older who were smoking

More information

Non-Communicable Diseases in the Caribbean Region

Non-Communicable Diseases in the Caribbean Region Non-Communicable Diseases in the Caribbean Region Dr. Shiyan Chao The World Bank Regional Workshop on Non-Communicable Diseases in the Caribbean Kingston, Jamaica May 28-30, 2012 Outline Why the World

More information

Strengthening evidence-based decision making for new vaccine introduction: PAHO s ProVac Initiative

Strengthening evidence-based decision making for new vaccine introduction: PAHO s ProVac Initiative http://www.paho.org/provac Strengthening evidence-based decision making for new vaccine introduction: PAHO s ProVac Initiative Cara Bess Janusz Immunization, PAHO 1 st Regional Dengue Symposium 3-4 November

More information

PUBLIC HEALTH UPDATE

PUBLIC HEALTH UPDATE PUBLIC HEALTH UPDATE Eric C. McDonald, MD, MPH, FACEP Medical Director, Epidemiology and Immunizations Services, Public Health Services County of San Diego Health and Human Services Agency Annual SoCal

More information

Progress Made in the Integration of EPI Costing and Planning

Progress Made in the Integration of EPI Costing and Planning Volume XXXV Number 5 Immunize and Protect Your Family October 2013 Progress Made in the Integration of EPI Costing and Planning If we compare the situation of the Expanded Program on Immunization (EPI)

More information

PAHO REPORT. Lessons Learned. on IPV Introduction and the Switch from topv to bopv in the Americas

PAHO REPORT. Lessons Learned. on IPV Introduction and the Switch from topv to bopv in the Americas PAHO REPORT Lessons Learned on IPV Introduction and the Switch from topv to bopv in the Americas Lessons learned on IPV introduction and the Switch from topv to bopv in the Americas Document Number: PAHO/FGL/017-026

More information

Regional Update EW 32, 2012 Influenza (August 21, h GMT; 12 h EST)

Regional Update EW 32, 2012 Influenza (August 21, h GMT; 12 h EST) Regional Update EW 32, 2012 Influenza (August 21, 2012-17 h GMT; 12 h EST) PAHO interactive influenza data: HUhttp://ais.paho.org/phip/viz/ed_flu.aspU Influenza Regional Reports: www.paho.org/influenzareports

More information

Role of Partnerships in Developing Innovative Vaccines: Brazil

Role of Partnerships in Developing Innovative Vaccines: Brazil Role of Partnerships in Developing Innovative Vaccines: Brazil SAGE Meeting, October 2010 Reinaldo Guimarães, M.D, MSc. Secretary of Science, Technology and Strategic Inputs Ministry of Health of Brazil

More information

Regional Update EW 14, 2013 Influenza and other respiratory viruses (April 16, 2013)

Regional Update EW 14, 2013 Influenza and other respiratory viruses (April 16, 2013) Regional Update EW 14, 2013 Influenza and other respiratory viruses (April 16, 2013) PAHO interactive influenza data: HUhttp://ais.paho.org/phip/viz/ed_flu.aspU Influenza Regional Reports: www.paho.org/influenzareports

More information

Regional Update EW 30 Influenza (August 9, h GMT; 12 h EST)

Regional Update EW 30 Influenza (August 9, h GMT; 12 h EST) Regional Update EW 30 Influenza (August 9, 2011-17 h GMT; 12 h EST) PAHO interactive influenza data: HUhttp://ais.paho.org/phip/viz/ed_flu.aspU Influenza Regional Reports: HUhttp://new.paho.org/hq/index.php?option=com_content&task=view&id=3352&Itemid=2469&to=2246U

More information

Diabetes Advocacy Experience

Diabetes Advocacy Experience Diabetes Advocacy Experience 1 Initial relevance of Diabetes Foot Clinic for Barbados Surgical bed occupancy 50% male ward and 80% female ward (Walrond & Ramesh, 1998) poor management of diabetes and the

More information

Deborah Chen MPH The Heart Foundation of Jamaica

Deborah Chen MPH The Heart Foundation of Jamaica Deborah Chen MPH The Heart Foundation of Jamaica The National Resuscitation Council Of Jamaica The Jamaica Coalition for Tobacco Control An alliance of organizations and individuals that collaborate to

More information

Zika virus transmission: ECDC adaptation of WHO's Zika virus country classification scheme 1

Zika virus transmission: ECDC adaptation of WHO's Zika virus country classification scheme 1 Zika virus transmission: ECDC adaptation of WHO's Zika virus country classification scheme 1 Country Region Country classification category for Zika transmission American Samoa American Samoa Areas with

More information

developing countries in Latin America?

developing countries in Latin America? . How have rotavirus vaccines worked in developing countries in Latin America? Brendan Flannery, Pan American Health Organization, Brazil and Lúcia De Oliveira, Immunization Unit/FCH, Washington, DC 9th

More information

r0 HEALTH HEALTH ORGANIZATION ORGANIZATION XXXIX Meeting Washington, D.C. September 1996 XLVIII Meeting Provisional Agenda Item 5.

r0 HEALTH HEALTH ORGANIZATION ORGANIZATION XXXIX Meeting Washington, D.C. September 1996 XLVIII Meeting Provisional Agenda Item 5. directing council regional committee t PAN AMERICAN WORLD r0 HEALTH HEALTH ORGANIZATION ORGANIZATION XXXIX Meeting Washington, D.C. September 1996 XLVIII Meeting Provisional Agenda Item 5. 7 CD39/17 (Eng.)

More information

Overview of the ProVac Initiative

Overview of the ProVac Initiative Overview of the ProVac Initiative Updated Dec. 2017 Goal of the ProVac Initiative Strengthen evidence-based decision making on immunization to sustain and further the public health impact of immunization

More information

HEALTH ORGANIZATION. ORGANIZATION XXXIX Meeting Washington, D.C. September 1996

HEALTH ORGANIZATION. ORGANIZATION XXXIX Meeting Washington, D.C. September 1996 directing council regional committee p )A PAN AMERICAN WORLD HEALTH HEALTH ORGANIZATION ORGANIZATION XXXIX Meeting Washington, D.C. September 1996 XLVIII Meeting Provisional Agenda Item 5.6 CD39/16 (Eng.)

More information

Translating Science to End HIV in Latin America and the Caribbean

Translating Science to End HIV in Latin America and the Caribbean Translating Science to End HIV in Latin America and the Caribbean Mexico City, Mexico, 17 th - 18 th and 21 st April IAS 2017 post-conference workshop, 17 April 2018 Challenges for PrEP and PEP Implementation

More information

Regional Update EW 43 Influenza (November 8, h GMT; 12 h EST)

Regional Update EW 43 Influenza (November 8, h GMT; 12 h EST) Regional Update EW 43 Influenza (November 8, 2011-17 h GMT; 12 h EST) PAHO interactive influenza data: HUhttp://ais.paho.org/phip/viz/ed_flu.aspU Influenza Regional Reports: www.paho.org/influenzareports

More information

Regional Update EW 22, 2013 Influenza and other respiratory viruses (June 11, 2013)

Regional Update EW 22, 2013 Influenza and other respiratory viruses (June 11, 2013) Regional Update EW 22, 2013 Influenza and other respiratory viruses (June 11, 2013) PAHO interactive influenza data: HUhttp://ais.paho.org/phip/viz/ed_flu.aspU Influenza Regional Reports: www.paho.org/influenzareports

More information

Stanley A. Plotkin ADVAC /10/2010 2:35 PM

Stanley A. Plotkin ADVAC /10/2010 2:35 PM How and dwh Why Vaccines are Made Stanley A. Plotkin ADVAC 1 2010 5/10/2010 2:35 PM 1 Vaccines 1. History of vaccination 2. The vaccine industry 3. Why vaccines are developed 4. The current problems of

More information

Xavier Sáez-Llorens Head of Infectious Diseases & Director of Clinical Research Hospital del Niño Dr. José Renán Esquivel, Panama 1

Xavier Sáez-Llorens Head of Infectious Diseases & Director of Clinical Research Hospital del Niño Dr. José Renán Esquivel, Panama 1 VACCINES PROGRESS AND CHALLENGES Xavier Sáez-Llorens Head of Infectious Diseases & Director of Clinical Research Hospital del Niño Dr. José Renán Esquivel, Panama 1 Conflicts of Interest Research grants

More information

Belize. Tobacco Control Report. Current Tobacco Use Prevalence 25% 21.8% 15.3%

Belize. Tobacco Control Report. Current Tobacco Use Prevalence 25% 21.8% 15.3% Belize Tobacco Control Report Current Tobacco Use Prevalence 25% 21.8% 3% Male Female Adults 15.3% Male Female Youth Adult data: percent of the population 15 years and older who were smoking any tobacco

More information

China Human Vaccine Industry Report, July 2017

China Human Vaccine Industry Report, July 2017 China Human Vaccine Industry Report, 2017-2021 2021 July 2017 STUDY GOAL AND OBJECTIVES This report provides the industry executives with strategically significant competitor information, analysis, insight

More information

26 APRIL-3 MAY 2014 FINAL REPORT

26 APRIL-3 MAY 2014 FINAL REPORT 26 APRIL-3 MAY 2014 FINAL REPORT Contents Overview: Vaccination Week in the Americas 2014... 3 Overview: World Immunization Week 2014... 4 VWA s 2014 Regional Communication Campaign... 5 Press Coverage...

More information

Analysis of Immunization Financing Indicators of the WHO-UNICEF Joint Reporting Form (JRF)

Analysis of Immunization Financing Indicators of the WHO-UNICEF Joint Reporting Form (JRF) Analysis of Immunization Financing Indicators of the WHO-UNICEF Joint Reporting Form (JRF) 2010-2015 Department of Immunization Vaccines and Biologicals, World Health Organization October 2017 Acknowledgements

More information

China Human Vaccine Industry Report, May 2012

China Human Vaccine Industry Report, May 2012 China Human Vaccine Industry Report, 2011-2012 May 2012 STUDY GOAL AND OBJECTIVES This report provides the industry executives with strategically significant competitor information, analysis, insight and

More information

Programme update. Prequalification of Vaccines

Programme update. Prequalification of Vaccines Programme update Prequalification of Vaccines UN Prequalification of Medicines, Diagnostics and Vaccines 6th Consultative Stakeholder Meeting 4 April 2011 David Wood, WHO/IVB/QSS Outline Good news - A

More information

Current Status in Latin America

Current Status in Latin America WHO International Consultation 15 to 17 October 2014 Munich, Germany JUSTIFICATION OF THE USE OF CT FOR INDIVIDUAL HEALTH ASSESSMENT OF ASYMPTOMATIC PEOPLE Current Status in Latin America Gloria Soto Giordani

More information

Marta-Louise Ackers, a Robert E Quick, a Christopher J Drasbek, b Lori Hutwagner c and Robert V Tauxe a

Marta-Louise Ackers, a Robert E Quick, a Christopher J Drasbek, b Lori Hutwagner c and Robert V Tauxe a O International Epldemiological Association 998 Printed in Great Britain International Journal of Epidemiology 998:27:-4 Are there national risk factors for epidemic cholera? The correlation between socioeconomic

More information

_flu.asp. States. North. The Caribbean and (Cuba, South. South. B was observed.

_flu.asp. States. North. The Caribbean and (Cuba, South. South. B was observed. North America: Influenza activity remained low in the sub-region with co-circulation of influenza A(H1N1)pdm09, A(H3N2) and influenza B. In the United States, no new humann infections with influenza A(H3N2)

More information

Ad-hoc Virtual TAG Meeting 2017

Ad-hoc Virtual TAG Meeting 2017 Ad-hoc Virtual TAG Meeting 2017 2 nd Ad-hoc Meeting of the Technical Advisory Group on Vaccine-preventable Diseases 10 March 2017 Washington, DC, USA TAG Members Dr. J. Peter Figueroa Professor Public

More information

מדינת ישראל. Tourist Visa Table

מדינת ישראל. Tourist Visa Table Updated 23/05/2017 מדינת ישראל Tourist Visa Table Tourist visa exemption is applied to national and official passports only, and not to other travel documents. Exe = exempted Req = required Press the first

More information

Current Status on the implementation of TB- HIV collaborative activities in the Americas. Results of a survey in the countries of the Region

Current Status on the implementation of TB- HIV collaborative activities in the Americas. Results of a survey in the countries of the Region Current Status on the implementation of TB- HIV collaborative activities in the Americas Results of a survey in the countries of the Region 2012 1 Acknowledgements We would like to express our gratitude

More information

Regional Update EW 44 Influenza (November 15, h GMT; 12 h EST)

Regional Update EW 44 Influenza (November 15, h GMT; 12 h EST) Regional Update EW 44 Influenza (November 15, 2011-17 h GMT; 12 h EST) PAHO interactive influenza data: http://ais.paho.org/phip/viz/ed_flu.asp Influenza Regional Reports: www.paho.org/influenzareports

More information

Regional Updates on CVD Trends and Actions: Latin America and the Caribbean

Regional Updates on CVD Trends and Actions: Latin America and the Caribbean Regional Updates on CVD Trends and Actions: Latin America and the Caribbean Beatriz Marcet Champagne, PhD Public Information-Gathering Session, Wash., DC, April 14, 2009 Institute of Medicine of the National

More information

46th DIRECTING COUNCIL 57th SESSION OF THE REGIONAL COMMITTEE

46th DIRECTING COUNCIL 57th SESSION OF THE REGIONAL COMMITTEE PAN AMERICAN HEALTH ORGANIZATION WORLD HEALTH ORGANIZATION 46th DIRECTING COUNCIL 57th SESSION OF THE REGIONAL COMMITTEE Washington, D.C., USA, 26-30 September 2005 Provisional Agenda Item 4.15 4 August

More information

Prevalence of Alcohol Consumption during Pregnancy and Fetal Alcohol Spectrum Disorder

Prevalence of Alcohol Consumption during Pregnancy and Fetal Alcohol Spectrum Disorder Prevalence of Alcohol Consumption during Pregnancy and Fetal Alcohol Spectrum Disorder Presented by Svetlana (Lana) Popova, MD, PhD, MPH Centre for Addiction and Mental Health, University of Toronto, PAHO/WHO

More information

PAHO HIV REPORT. Progress of Implementation of the World Health Organization. Drug Resistance Strategy. in Latin America and the Caribbean:

PAHO HIV REPORT. Progress of Implementation of the World Health Organization. Drug Resistance Strategy. in Latin America and the Caribbean: OPS/FCH/HI/04-10.I PAHO HIV REPORT Progress of Implementation of the World Health Organization Drug Resistance Strategy in Latin America and the Caribbean: 2006 2009 June 2010 1 Progress of Implementation

More information